論文・技術情報追加のお知らせ

1. A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide.

ビクテグラビル等配合剤のFAERS市販後安全性プロファイル。

対象DB：FAERS

2. Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS.

セマグチドとチルゼパチドの有害事象報告パターンの比較解析。

対象DB：FAERS

3. The reporting phenotype of penile fracture after collagenase clostridium histolyticum for Peyronie's disease: an indication-restricted FAERS study.

コラゲナーゼ注射による陰茎折症報告フェノタイプの解析。

対象DB：FAERS

4. Cardiac adverse event signals of Bruton's tyrosine kinase inhibitors as primary suspect and in co-reported regimens: a large-scale FAERS pharmacovigilance study.

BTK阻害薬単剤および併用療法における心臓有害事象シグナル。

対象DB：FAERS

5. Association Between Acute Vulvar Ulcers and Gene-Based COVID-19 Vaccines.

遺伝子型COVID-19ワクチンと急性外陰部潰瘍発症の関連。

対象DB：FAERS,VAERS

6. Pancreatic and Gallbladder Adverse Events Associated with Tirzepatide in Obesity Management: A Scoping Review.

肥満管理でのチルゼパチドの膵・胆嚢有害事象レビュー。

対象DB：EudraVigilance,FAERS

7. Fifteen-year real-world pharmacovigilance of multiple sclerosis disease-modifying therapies: adverse event profiles, drug-specific safety signals and clinical implications.

多発性硬化症治療薬における15年間の有害事象プロファイル。

対象DB：FAERS

8. Non-PML neuroinvasive infections reported with multiple sclerosis disease-modifying therapies: a mechanism-based pharmacovigilance study, 2004-2025.

多発性硬化症治療薬に伴う非PML神経侵襲性感染症の解析。

対象DB：FAERS

9. Age-stratified reporting of immune checkpoint inhibitor-associated myocarditis: disproportionality is amplified in older adults, with implications for geriatric oncology.

高齢者におけるICI関連心筋炎報告の年齢層別不均衡分析。

対象DB：FAERS

10. Real-world safety of vericiguat as a fifth-line agent in heart failure: a pharmacovigilance study of quintuple therapy.

心不全でのベルイシグアト5剤併用時のリアルワールド安全性。

対象DB：FAERS

11. Drug-drug Interaction Signals for Sexual Dysfunction with Antidepressants and Antipsychotics: A Pharmacovigilance-pharmacodynamic Study.

抗うつ薬と抗精神病薬併用による性機能障害の相互作用シグナル。

対象DB：FAERS

12. Infection-related adverse events associated with T-cell-engaging bispecific agents: A real-world pharmacovigilance study using FAERS/AEMS.

T細胞結合性二重特異性抗体に伴う感染症関連有害事象の解析。

対象DB：FAERS

13. Comparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS database.

FAERSに基づくGLP-1受容体作動薬の心臓有害事象比較。

対象DB：FAERS

14. Postmarketing reporting profile of mirikizumab in ulcerative colitis: a disproportionality analysis of FAERS reports.

潰瘍性大腸炎におけるミリキズマブの市販後有害事象報告解析。

対象DB：FAERS

15. Real-World Safety Profile of Mirvetuximab Soravtansine: A Population-Based Pharmacovigilance Study Leveraging FAERS and EudraVigilance Databases.

ミルベツキシマブのリアルワールド安全性多国籍DB解析。

対象DB：EudraVigilance,FAERS

16. Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance.

セマグチドとパニック発作の関連に関する不均衡分析とバイアス。

対象DB：FAERS

17. Effect of voclosporin on psychiatric disorders: real-world pharmacovigilance and genetic evidence.

ボクロスポリンの精神障害への影響に関する自発報告と検証。

対象DB：FAERS

18. Adverse Event Reporting Patterns Associated with Concomitant Use of 5-HT3 and NK-1 Receptor Antagonists: A Large-Scale Spontaneous-Reporting Analysis.

制吐薬（5-HT3・NK-1拮抗薬）併用時の有害事象解析。

対象DB：FAERS

19. Multilayered Prioritization of Graph Attention Autoencoder-Derived Drug Repurposing Candidates for COVID-19.

グラフ注意自己符号化器を用いたCOVID-19治療薬の同定。

対象DB：FAERS

20. Characterization of Psychiatric Adverse Events Reported with Levetiracetam in the FDA Adverse Event Reporting System (FAERS).

レベチラセタムの精神・行動関連副作用のFAERS解析。

対象DB：FAERS

21. Adverse Event Reporting Patterns of Tobacco Cessation Medications in Korea: A Disproportionality Analysis.

韓国全国データを用いた禁煙治療薬の有害事象報告パターン解析。

対象DB：FAERS,KAERS

22. Infectious Complications and Toxicities of the Teclistamab Plus Daratumumab Combination in Relapsed or Refractory Multiple Myeloma: A Disproportionality and Drug-Interaction Analysis of the FDA Adverse Event Reporting System.

難治性骨髄腫でのテクリスタマブ・ダラツムマブ併用の感染毒性。

対象DB：FAERS

23. Cardiovascular adverse events of tocilizumab and baricitinib in COVID-19 and rheumatoid arthritis: A real-world disproportionality and machine learning analysis.

COVID-19等でのトシリズマブの心血管副作用解析。

対象DB：FAERS,KAERS

24. Reporting signals of selected extrapyramidal adverse events with four newer second-generation antipsychotics: a disproportionality analysis of FAERS spontaneous reports.

新規第二世代抗精神病薬4種における錐体外路症状シグナル比較。

対象DB：FAERS

25. Oral Health-Related Adverse Events of GLP-1 Receptor Agonists.

GLP-1受容体作動薬での口腔健康関連副作用レビュー。

対象DB：FAERS

26. Delusions of Parasitosis Associated With Drug Exposure.

薬剤曝露に関連する寄生虫妄想症の報告傾向レビュー。

対象DB：FAERS

27. Signal Mining of Adverse Events of Antiangiogenic Drugs in Colorectal Cancer Based on the FDA Adverse Event Reporting System (FAERS) Database.

大腸がんにおける血管新生阻害薬の有害事象シグナルマイニング。

対象DB：EudraVigilance,FAERS

28. Real-World Serologic Responses and Recorded Medically Attended Events After the Live Attenuated MAV/06-Strain Varicella Vaccine in Adolescents and Adults: A Retrospective Cohort Study.

青年・成人における水痘生ワクチンの抗体応答と受診事象の実態。

対象DB：FAERS,KAERS,VAERS

29. Temporal, Phenotypic, and Treatment-Context Heterogeneity in Retinal Vasculitis Reporting with Pegcetacoplan: A United States Pharmacovigilance Study.

ペグセタコプランに伴う網膜血管炎報告の不均一性と背景解析。

対象DB：CVAR,FAERS

30. Disproportionate reporting of acute renal events and chronic kidney disease with proton pump inhibitors and the potassium-competitive acid blocker vonoprazan: A time-to-onset and signal-detection analysis of the FAERS and JADER databases.

PPI・ボノプラザンに伴う急性・慢性腎障害報告の比較。

対象DB：FAERS,JADER

31. Thrombotic events associated with thrombopoietin receptor agonists in children with immune thrombocytopenia: A safety analysis of clinical studies and FDA pharmacovigilance database.

小児ITPにおけるTPO受容体作動薬関連血栓イベントの評価。

対象DB：FAERS

32. Musculoskeletal Adverse Event Signals Associated With Semaglutide, Liraglutide, and Tirzepatide in the US FDA Adverse Event Reporting System.

GLP-1作動薬等における筋骨格系副作用シグナル解析。

対象DB：FAERS

33. Hepatobiliary Adverse Events Associated With Avacopan: Analysis of the JADER Database.

アバコパン関連肝胆道系有害事象のJADERデータ解析。

対象DB：JADER

34. Characteristics of Hypocalcemia-related Reports in the JADER Database: A Pharmacovigilance Study.

薬剤性低カルシウム血症報告のJADERデータ解析。

対象DB：JADER

35. Renal injury phenotypes with ICI-VEGFR-TKI combinations in renal cell carcinoma: active-comparator analyses in FAERS and JADER.

腎細胞がんICI・TKI併用時の腎障害フェノタイプ解析。

対象DB：JADER

36. Disproportionality Analysis of Acute Kidney Injury Reports Associated with Sacubitril/Valsartan (ARNI) in the Japanese Adverse Drug Event Report Database.

サクビトリルバルサルタン関連急性腎障害のJADER解析。

対象DB：JADER

37. Spectroscopic and structural characterization of human amniotic membrane after washing with plasma-activated water.

プラズマ活性水洗浄によるヒト羊膜の分光学的・構造的特性変化。

対象DB：JADER

38. Urinary tract and genital infections with dapagliflozin and empagliflozin across type 2 diabetes, heart failure, and chronic kidney disease: An indication- and sex-stratified disproportionality analysis of eudravigilance reports.

SGLT2阻害薬の尿路・性器感染症リスクに関する多層解析。

対象DB：EudraVigilance

39. Safety of Oral Echinacea Preparations: Systematic Review and Meta-Analysis in the Context of Therapeutic Benefit.

経口エキナセア製剤の安全性と有効性に関するメタアナリシス。

対象DB：EudraVigilance

40. Post-Marketing Reporting Patterns of Ceftazidime-Avibactam and Ceftolozane-Tazobactam: Analysis of Adverse Event Reports from EudraVigilance.

新規抗緑膿菌抗菌薬2種の市販後有害事象パターンの欧州解析。

対象DB：EudraVigilance

41. Comparative Reporting Patterns of Rabeprazole and Other Proton Pump Inhibitors in EudraVigilance: A System Organ Class-Level Disproportionality Analysis.

ラベプラゾールと他PPIの器官別大分類有害事象の比較解析。

対象DB：EudraVigilance

42. Assessing the Safety of Estro-Progestin and Progestin-only drugs: A Signal Detection Study of Meningioma Reports in EudraVigilance.

エストロゲン・黄体ホルモン製剤と髄膜腫リスクのシグナル解析。

対象DB：EudraVigilance

43. Antineoplastic therapies associated with venous thromboembolism: disproportionality analysis of the WHO database.

がん治療薬に伴う静脈血栓塞栓症リスクのWHO自発報告解析。

対象DB：VigiBase

44. Differences in ventricular tachyarrhythmia and sudden cardiac death reporting among antipsychotics: A VigiBase analysis.

抗精神病薬間における心室性不整脈と心臓突然死報告の比較評価。

対象DB：VigiBase

45. Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase).

GLP-1関連薬の神経精神系有害事象VigiBase解析。

対象DB：VigiBase

46. Intensity of End-of-Life Care Among Patients with Cerebral Palsy: A 12-Year Nationwide Study.

脳性麻痺患者における終末期医療の強度に関する12年間の調査。

対象DB：DPC

47. Machine Learning-Based Prediction of Major Postoperative Complications After Noncardiac Surgery Under General Anesthesia Using Routinely Available Electronic Health Record Data: Retrospective Multicenter Development and Validation Study.

機械学習を用いた非心臓手術後の主要術後合併症予測モデル開発。

対象DB：DPC

48. Impact of the COVID-19 Pandemic on Inpatient Colorectal Cancer Treatment in Japan: An Interrupted Time Series Analysis Using a National Administrative Database.

COVID-19流行が日本の大腸がん入院治療に与えた影響。

対象DB：DPC

49. Development and Validation of a Next-Generation Time-Driven Activity-Based Costing Model for Quantifying Uncertainty: An Empirical Study of Fuzzy-Logic Time-Driven Activity-Based Costing Using Surgical System Data.

手術システムデータを用いた不確実性対応原価計算モデルの開発。

対象DB：DPC

50. Epidemiology of hospitalized strongyloidiasis in Japan: A nationwide administrative database study.

日本における糞線虫症入院患者の全国疫学と臨床実態調査。

対象DB：DPC

51. Association Between Anaerobic Coverage and Clinical Outcomes in Patients with Lung Abscess: A Nationwide Database Study in Japan.

肺膿瘍患者における嫌気性菌カバー抗菌薬と臨床転帰の関連性。

対象DB：DPC

52. Frequencies of thyroid-related diagnoses and dyslipidemia among Japanese women with menstrual-related disorders aged under 40 years: A nationwide cross-sectional study using health insurance claims data.

月経随伴症の若年女性における甲状腺疾患・脂質異常症の頻度。

対象DB：JMDC

53. Medication background of Japanese men undergoing prostate needle biopsy: A medication profile based on the number of medications and drug classes.

前立腺生検を受ける日本人男性の多剤併用・処方背景の実態調査。

対象DB：MDV

54. Comparative treatment effects of direct oral anticoagulants versus warfarin for nonvalvular atrial fibrillation in clinical practice vary over time due to channelling.

心房細動でのDOAC対ワルファリン効果の経時的変化。

対象DB：CPRD

55. Phenome-wide Longitudinal Association Study of Hospital-recorded Comorbidity in Psoriasis.

乾癬患者における入院併存疾患の縦断的フェノムワイド関連解析。

対象DB：CPRD

56. Incidence of degenerative cervical myelopathy: findings from an English population-based study.

英国住民コホートにおける変形性頚椎症性脊髄症の発症率調査。

対象DB：CPRD

57. Cardiovascular outcomes in COPD, obstructive sleep apnoea and the overlap syndrome.

COPD・閉塞性睡眠時無呼吸の重複症候群における心血管転帰。

対象DB：CPRD

58. Cancer incidence following platelet count and C-reactive protein testing across ethnic groups in English primary care: a cohort study of 5 million patients.

血小板数・CRP検査値とがん発症リスクの関連性調査。

対象DB：CPRD

59. Inequality in healthy lifespan after surgery: a longitudinal population study.

手術後の健康寿命における社会経済的格差に関する長期コホート。

対象DB：CPRD

60. LDL-C target attainment and risk of revision following knee and hip replacements: real-world evidence from a target trial emulation study.

人工関節置換術後のLDL-C目標達成と再置換リスクの関連性。

対象DB：THIN

61. Co-Occurrence Patterns of Symptom and Functional Burden Associated with Tofacitinib and Upadacitinib: A Multidimensional Analysis of Spontaneous Reports in Rheumatoid Arthritis.

トファシチニブ等でのRA患者の症状・機能負荷共起解析。

対象DB：CVAR

62. Association of co-administration of neurokinin-1 receptor antagonists and dexamethasone with new-onset diabetes in patients receiving chemotherapy: a retrospective cross-sectional study using health claims database in Japan.

化学療法時のNK1受容体拮抗薬・デキサメタゾン併用と糖尿病。

対象DB：DeSC

63. Denosumab, clinical fractures, and osteonecrosis of the jaw in hemodialysis patients: a comparative study.

血液透析患者でのデノスマブ投与と骨折・顎骨壊死リスクの比較。

対象DB：DeSC